NO20004153L - Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet - Google Patents

Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet

Info

Publication number
NO20004153L
NO20004153L NO20004153A NO20004153A NO20004153L NO 20004153 L NO20004153 L NO 20004153L NO 20004153 A NO20004153 A NO 20004153A NO 20004153 A NO20004153 A NO 20004153A NO 20004153 L NO20004153 L NO 20004153L
Authority
NO
Norway
Prior art keywords
central nervous
nervous system
transcription
estradiol
oestrogen
Prior art date
Application number
NO20004153A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004153D0 (no
Inventor
Vladimir Patchev
Michael Oettel
Ina Thieme
Sigfrid Schwarz
Wolfgang Roemer
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/de
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of NO20004153D0 publication Critical patent/NO20004153D0/no
Publication of NO20004153L publication Critical patent/NO20004153L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20004153A 1998-02-20 2000-08-18 Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet NO20004153L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (de) 1998-05-15 1998-05-15 Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem
PCT/DE1999/000353 WO1999042108A1 (de) 1998-02-20 1999-02-10 Pharmazeutische präparate zur gezielten substitution des estrogenmangels im zentralnervensystem

Publications (2)

Publication Number Publication Date
NO20004153D0 NO20004153D0 (no) 2000-08-18
NO20004153L true NO20004153L (no) 2000-10-09

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004153A NO20004153L (no) 1998-02-20 2000-08-18 Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet

Country Status (24)

Country Link
EP (1) EP1056460B1 (tr)
JP (1) JP2002503694A (tr)
KR (1) KR20010041107A (tr)
CN (1) CN1291102A (tr)
AT (1) ATE252388T1 (tr)
AU (1) AU739071C (tr)
BG (1) BG104689A (tr)
BR (1) BR9909205A (tr)
CA (1) CA2321498A1 (tr)
CZ (1) CZ291764B6 (tr)
DE (1) DE59907446D1 (tr)
EA (1) EA002707B1 (tr)
EE (1) EE03906B1 (tr)
HU (1) HUP0100742A3 (tr)
ID (1) ID27069A (tr)
IL (1) IL137727A0 (tr)
IS (1) IS5571A (tr)
NO (1) NO20004153L (tr)
NZ (1) NZ506049A (tr)
PL (1) PL342313A1 (tr)
SK (1) SK12152000A3 (tr)
TR (1) TR200002400T2 (tr)
UA (1) UA57830C2 (tr)
WO (1) WO1999042108A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253318T3 (es) * 2001-11-07 2006-06-01 Schering Ag Cribado in vitro de ligandos del receptor de estrogeno.
CN112189624A (zh) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
PL342313A1 (en) 2001-06-04
EP1056460B1 (de) 2003-10-22
CN1291102A (zh) 2001-04-11
EE200000477A (et) 2001-12-17
KR20010041107A (ko) 2001-05-15
AU2920999A (en) 1999-09-06
NZ506049A (en) 2002-09-27
CZ291764B6 (cs) 2003-05-14
JP2002503694A (ja) 2002-02-05
DE59907446D1 (de) 2003-11-27
BG104689A (en) 2001-04-30
EA002707B1 (ru) 2002-08-29
CZ20002938A3 (cs) 2001-01-17
WO1999042108A1 (de) 1999-08-26
TR200002400T2 (tr) 2000-11-21
EP1056460A1 (de) 2000-12-06
CA2321498A1 (en) 1999-08-26
ATE252388T1 (de) 2003-11-15
HUP0100742A3 (en) 2002-07-29
UA57830C2 (uk) 2003-07-15
IL137727A0 (en) 2001-10-31
ID27069A (id) 2001-02-22
EA200000858A1 (ru) 2001-04-23
IS5571A (is) 2000-07-24
SK12152000A3 (sk) 2001-02-12
BR9909205A (pt) 2000-11-14
EE03906B1 (et) 2002-12-16
NO20004153D0 (no) 2000-08-18
HUP0100742A2 (hu) 2001-09-28
AU739071C (en) 2002-04-11
AU739071B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO1996019568A3 (en) Stabilized ribozyme analogs
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
WO1998027929A3 (de) Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder
TR199800648A1 (tr) Iki veya daha fazla etken madde için ilaç verme sistemi.
MXPA04001114A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
EP1023315A4 (en) METHODS AND PREPARATIONS FOR DESTRUCTING SPECIFIC PROTEINS
DE59901020D1 (de) 14,15-cyclopropanosteroide der 19-norandrostan-reihe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
DE59510626D1 (de) Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
MX9601994A (es) Profarmacos de derivados de paclitaxel.
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
NO20004153L (no) Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet
ES2136581A1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
TNSN96016A1 (fr) Utilisation de phenylcyclohexylcarboxamides
PT800579E (pt) Veiculos de distribuicao de genes de combinacao
DE59712593D1 (de) Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie
AU8624198A (en) 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments.
Kells et al. AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning
BR0113618A (pt) 17-metilenoesteróides, processos para a sua preparação e composições farmacêuticas contendo estes compostos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application